Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat in pediatric CKD anemia
NCT04925011Phase 3Unknown
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of roxadustat in anemia of chronic kidney disease (CKD-A). Primary endpoint: Proportion of patients with mean Hb >= 11.0 g/dL. Status: unknown.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04925011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925011.